Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)
Close on Nov 17, 2026Market cap $1.69BP/E –Yield –
Braveheart Bio price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
No price to sales ratio figures for Braveheart Bio
Braveheart Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?